Subscribe To
FOLD / Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease
FOLD News
By Seeking Alpha
October 31, 2023
Amicus Therapeutics: The Right Play Now
Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA a more_horizontal
By Zacks Investment Research
September 29, 2023
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease. more_horizontal
By Zacks Investment Research
September 20, 2023
3 Stocks Worth a Watch for Solid Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (V more_horizontal
By Zacks Investment Research
August 9, 2023
Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises i more_horizontal
By Seeking Alpha
August 8, 2023
Amicus Therapeutics Inc. (FOLD) Q2 2023 Earnings Call Transcript
Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice Presiden more_horizontal
By Zacks Investment Research
August 7, 2023
Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)
Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal
By Zacks Investment Research
August 3, 2023
3 Top Breakout Stocks to Invest in for Excellent Returns
First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today. more_horizontal
By GlobeNewsWire
July 31, 2023
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and li more_horizontal